Geode Capital Management
APGE icon

Geode Capital Management’s Apogee Therapeutics APGE Stock Holding History

Geode Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175M Buy
1,314,868
+97,579
+8% +$8.79M 0.01% 878
2026
Q1 		$102M Buy
1,217,289
+158,204
+15% +$11.5M 0.01% 1066
2025
Q4 		$80M Buy
1,059,085
+166,882
+19% +$10.5M ﹤0.01% 1221
2025
Q3 		$35.5M Buy
892,203
+109,562
+14% +$4.18M ﹤0.01% 1691
2025
Q2 		$34M Sell
782,641
-53,054
-6% -$2.02M ﹤0.01% 1645
2025
Q1 		$31.2M Buy
835,695
+19,582
+2% +$757K ﹤0.01% 1648
2024
Q4 		$37M Sell
816,113
-7,726
-0.9% -$394K ﹤0.01% 1623
2024
Q3 		$48.4M Buy
823,839
+82,978
+11% +$3.98M ﹤0.01% 1448
2024
Q2 		$29.2M Sell
740,861
-20,163
-3% -$979K ﹤0.01% 1715
2024
Q1 		$50.6M Buy
761,024
+319,552
+72% +$14M ﹤0.01% 1350
2023
Q4 		$12.3M Buy
441,472
+40,236
+10% +$807K ﹤0.01% 2218
2023
Q3 		$8.55M Buy
+401,236
New +$8.84M ﹤0.01% 2363

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Geode Capital Management's APGE Position: Q2 2026 in Review

Geode Capital Management increased its Apogee Therapeutics (APGE) stake by 8% in Q2 2026, buying an estimated $8.79M and bringing the position to 1,314,868 shares worth $175M. The position accounts for 0.01% of the portfolio, ranked #878.

Geode Capital Management first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Geode Capital Management held 1,314,868 shares of Apogee Therapeutics worth $175M as of Q2 2026.
  • Geode Capital Management bought 97,579 Apogee Therapeutics shares in Q2 2026, an estimated $8.79M.
  • Apogee Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #878 holding.
  • Geode Capital Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.